The CCK-A receptor gene possibly associated with auditory hallucinations in schizophrenia

European Psychiatry

Volumn 14, Issue 2, 1999, Pages 67-70

  Wei, J ^a   Hemmings, G P ^a  

^a Schizophrenia Assoc of Gt Britain   (United Kingdom)

Author keywords

Auditory hallucination; Cholecystokinin (CCK) receptor; Gene; Polymerase chain reaction (PCR); Restriction fragment length polymorphisms (RFLPs); Schizophrenia

Indexed keywords

CHOLECYSTOKININ A RECEPTOR;

ALLELE; ARTICLE; AUDITORY HALLUCINATION; EXON; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA;

EID: 0033118143     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(99)80719-6     Document Type: Article

References (26)

1. Albus M, von Gellhorn K, Münch U, Naber D, Ackenheil MA. Double-blind study with ceruletide in chronic schizophrenic patients: biochemical and clinical results. Psychiatr Res 1986; 19: 1-7.
2. Andreasen NC, Flaum M, Swayze VW, Tyrrell G, Arndt S. Positive and negative symptoms in schizophrenia: a critical reappraisal. Arch Gen Psychiatr 1990; 47: 615-21.
3. Arinami, T, Itokawa M, Enguchi H, Tagaya H, Yano S, Shimizu H, et al. Association of dopamine D2 receptor molecular variant with schizophrenia. Lancet 1994; 343: 703-4.
4. Bachus SE, Hyde TM, Herman MM, Egan MF, Kleinman JE. Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics. J Psychiatr Res 1997; 31: 233-56.
5. Cardno AG, McGuffin P. The molecular genetics of schizophrenia. Neuropathol Appl Neurobiol 1994; 20: 344-9.
6. Crawley JN. Choecystokinin-dopamine interactions. Trends Pharmacol Sci 1991; 12: 232-6.
7. Deleon J, Cuesta MJ, Peralta V. Delusions and hallucinations in schizophrenic patients. Psychopathology 1993; 26: 286-91.
8. 4 receptor and tyrosine hydroxylase genes. Acta Psychiatr Scand 1997; 96: 295-300.
9. Hillman H. A study of 131 patients with schizophrenia and provision for them. Int J Health Care Quality Assurance 1998; 11: 102-12.
10. Gariano RF, Groves PM. A mechanism for the involvement of co-localized neuropeptides in the action of antipsychotic drugs. Biol Psychiatry 1989; 26: 303-14.
11. Inoue H, Iannotti CA, Welling CM, Veile R, Donis-Keller H, Permutt MA. Human cholecystokinin type A receptor gene: cytogenetic localization, physical mapping, and identification of two missense variants in patients with obesity and non-insulin-dependent diabetes mellitus (NIDDM). Genomics 1997; 42: 331-5.
12. Jönsson E, Brene S, Geijer Th, Terenius L, Tylec A, Persson ML, et al. A search for association between schizophrenia and dopamine-related alleles. Eur Arch Psychiatr Clin Neurosci 1996; 246: 297-304.
13. Kalivas PW. Interactions between neuropeptides and dopamine neurones in the ventromedial mesencephalon. Neurosci Biobehav Rev 1985; 94: 573-87.
14. Karayiorgou M, Gogos JA. A turning point in schizophrenia genetics. Neuron 1997; 19: 967-79.
15. Nair NPV, Lal S, Bloom DM. Cholecystokinin peptides, dopamine and schizophrenia - A review. Prog Neuro-Psychopharmacol Biol Psychiatry 1985; 9: 515-24.
16. Nair NPV, Lal S, Bloom DM. Cholecystokinin and schizophrenia. Prog Brain Res 1986; 65: 237-58.
17. Nemeroff CB. Neuropeptides and schizophrenia: a critical review. In: Tamminga CA, Schulz SC, eds. Advances in Neuropsychiatry and Psychopharmacology Vol I. New York: Raven Press; 1991. p. 77-89.
18. Plomin R, Owen MJ, McGuffin P. The genetic basis of complex human behaviors. Science 1994; 264: 1773-9.
19. B antagonist LY262691 decreases midbrain dopine unit activity. Eur J Pharmacol 1991; 209: 135-8.
20. Song I, Brown DR, Wiltshire RN, Gantz I, Trent JM, Yamada T. The human gastrin/cholecystokinin type B receptor gene alternative splice donor site in exon 4 generates two variant mRNAs. Proc Natl Acad Sci USA 1993; 90: 9085-9.
21. Terwilliger JD, Ott J. A haplotype-based 'haplotype relative risk' approach to detecting allelic associations. Hum Hered 1992; 42: 337-46.
22. Tsuang MT, Faraone SV. The case for heterogeneity in the etiology of schizophrenia. Schizophr Res 1995; 17: 161-75.
23. Virgo L, Humphries C, Mortimer A, Barnes T, Hirsch S, de Belleroche J. Cholecystokinin messenger RNA deficit in frontal and temporal cerebral cortex in schizophrenia. Biol Psychiatry 1995; 37: 694-701.
24. Wank SA. Cholecystokinin receptors. Am J Physiol 1995; 269: G628-46.
25. Williams NM, Cardno AG, Murphy KC, Jones LA, Asherson P, McGuffin P, et al. Association between schizophrenia and microsatellite polymorphism at the dopamine D5 receptor gene. Psychiatr Genet 1997; 7: 83-5.
26. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1955; 19: 251-3.